These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18695158)

  • 21. [The impact of levodopa-carbidopa intestinal gel on health-related quality of life in Parkinson's disease].
    Kovács N; Aschermann Z; Ács P; Bosnyák E; Deli G; Janszky J; Komoly S
    Ideggyogy Sz; 2014 Jul; 67(7-8):245-50. PubMed ID: 25509365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs.
    Pålhagen SE; Sydow O; Johansson A; Nyholm D; Holmberg B; Widner H; Dizdar N; Linder J; Hauge T; Jansson R; Bergmann L; Kjellander S; Marshall TS
    Parkinsonism Relat Disord; 2016 Aug; 29():17-23. PubMed ID: 27318707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
    Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R
    JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
    Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
    Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
    Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between fatigue and other motor and non-motor symptoms in Parkinson's disease patients.
    Solla P; Cannas A; Mulas CS; Perra S; Corona A; Bassareo PP; Marrosu F
    J Neurol; 2014 Feb; 261(2):382-91. PubMed ID: 24375016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of D1/D5 Partial Agonist PF-06412562 in Parkinson's Disease following Oral Administration.
    Papapetropoulos S; Liu W; Duvvuri S; Thayer K; Gray DL
    Neurodegener Dis; 2018; 18(5-6):262-269. PubMed ID: 30453303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA; Hauser RA; Pahwa R; Isaacson SH; Fernandez HH; Lew M; Saint-Hilaire M; Pourcher E; Lopez-Manzanares L; Waters C; Rudzínska M; Sedkov A; Batycky R; Oh C;
    Lancet Neurol; 2019 Feb; 18(2):145-154. PubMed ID: 30663606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When do the symptoms of autonomic nervous system malfunction appear in patients with Parkinson's disease?
    De Luka SR; Svetel M; Pekmezović T; Milovanović B; Kostić VS
    Vojnosanit Pregl; 2014 Apr; 71(4):346-51. PubMed ID: 24783414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients.
    Slevin JT; Fernandez HH; Zadikoff C; Hall C; Eaton S; Dubow J; Chatamra K; Benesh J
    J Parkinsons Dis; 2015; 5(1):165-74. PubMed ID: 25588353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial.
    Tolosa E; Hernández B; Linazasoro G; López-Lozano JJ; Mir P; Marey J; Kulisevsky J
    J Neural Transm (Vienna); 2014 Apr; 121(4):357-66. PubMed ID: 24253234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.
    Mao ZL; Modi NB
    J Clin Pharmacol; 2016 Aug; 56(8):974-82. PubMed ID: 26632091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study.
    Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T
    J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.